D
David B. Shackelford
Researcher at University of California, Los Angeles
Publications - 50
Citations - 9871
David B. Shackelford is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Lung cancer & PI3K/AKT/mTOR pathway. The author has an hindex of 22, co-authored 42 publications receiving 8167 citations. Previous affiliations of David B. Shackelford include University of California, San Diego & Salk Institute for Biological Studies.
Papers
More filters
Journal ArticleDOI
AMPK phosphorylation of raptor mediates a metabolic checkpoint.
Dana M. Gwinn,David B. Shackelford,Daniel F. Egan,Maria M. Mihaylova,Annabelle Mery,Debbie S. Vasquez,Benjamin E. Turk,Reuben J. Shaw +7 more
TL;DR: AMPK directly phosphorylates the mTOR binding partner raptor on two well-conserved serine residues, and this phosphorylation induces 14-3-3 binding to raptor, uncovering a conserved effector of AMPK that mediates its role as a metabolic checkpoint coordinating cell growth with energy status.
Journal ArticleDOI
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Daniel F. Egan,David B. Shackelford,Maria M. Mihaylova,Sara Gelino,Rebecca A. Kohnz,William B. Mair,Debbie S. Vasquez,Aashish Joshi,Dana M. Gwinn,Rebecca C. Taylor,John M. Asara,James A. J. Fitzpatrick,Andrew Dillin,Benoit Viollet,Mondira Kundu,Malene Hansen,Reuben J. Shaw +16 more
TL;DR: Reconstitution of ULK1-deficient cells with a mutant ULK2 that cannot be phosphorylated by AMPK revealed that such phosphorylation is required for mitochondrial homeostasis and cell survival during starvation.
Journal ArticleDOI
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.
TL;DR: The connection of AMPK with several tumour suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants further investigation in patients with cancer.
Journal ArticleDOI
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford,David B. Shackelford,Evan R. Abt,Laurie Gerken,Debbie S. Vasquez,Atsuko Seki,Mathias Leblanc,Liu Wei,Michael C. Fishbein,Johannes Czernin,Paul S. Mischel,Reuben J. Shaw +11 more
TL;DR: Phenformin is suggested as a cancer metabolism-based therapeutic to selectively target LKB1-deficient tumors, resulting in prolonged survival in these tumors.
Journal ArticleDOI
mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
David B. Shackelford,Debbie S. Vasquez,Jacqueline Corbeil,Shulin Wu,Mathias Leblanc,Chin-Lee Wu,David R. Vera,Reuben J. Shaw +7 more
TL;DR: It is demonstrated here that polyps from human Peutz-Jeghers patients similarly exhibit up-regulated mTORC1 signaling, HIF-1α, and GLUT1 levels, and like LKB1+/− mice, the FDG-PET signal in the GI tract of these mice is abolished by rapamycin treatment.